BR112012003759A2 - "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer." - Google Patents
"anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer."Info
- Publication number
- BR112012003759A2 BR112012003759A2 BR112012003759A BR112012003759A BR112012003759A2 BR 112012003759 A2 BR112012003759 A2 BR 112012003759A2 BR 112012003759 A BR112012003759 A BR 112012003759A BR 112012003759 A BR112012003759 A BR 112012003759A BR 112012003759 A2 BR112012003759 A2 BR 112012003759A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosis
- cancer detection
- cmet antibody
- cmet
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23586409P | 2009-08-21 | 2009-08-21 | |
| EP09305777A EP2287197A1 (en) | 2009-08-21 | 2009-08-21 | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| US34800510P | 2010-05-25 | 2010-05-25 | |
| PCT/EP2010/062271 WO2011020925A1 (en) | 2009-08-21 | 2010-08-23 | Anti-cmet antibody and its use for the detection and the diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012003759A2 true BR112012003759A2 (pt) | 2017-07-11 |
Family
ID=41571045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012003759A BR112012003759A2 (pt) | 2009-08-21 | 2010-08-23 | "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer." |
Country Status (19)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| MX2013002084A (es) | 2010-08-31 | 2013-05-09 | Genentech Inc | Biomarcadores y metodos de tratamiento. |
| KR101444837B1 (ko) | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| SG11201400724SA (en) | 2011-09-19 | 2014-04-28 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
| ES2736999T3 (es) * | 2011-11-21 | 2020-01-09 | Taivex Therapeutics Corp | Biomarcadores para cánceres que responden a moduladores de la actividad de Hec1 |
| GB201121914D0 (en) | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Method for patient selection |
| WO2013169532A1 (en) * | 2012-05-09 | 2013-11-14 | Eli Lilly And Company | Anti-c-met antibodies |
| CN105050618B (zh) * | 2012-06-21 | 2018-11-16 | 索伦托治疗有限公司 | 与c-Met结合的抗原结合蛋白 |
| JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
| US10214593B2 (en) | 2013-04-02 | 2019-02-26 | Samsung Electronics Co., Ltd. | Anti-idiotype antibody against anti-c-MET antibody |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| WO2015031626A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015031614A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015032695A1 (en) * | 2013-09-09 | 2015-03-12 | Ventana Medical Systems, Inc. | Scoring method for mesothelin protein expression |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| RU2016144405A (ru) | 2014-05-23 | 2018-06-26 | Дженентек, Инк. | MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| US10544210B2 (en) * | 2015-02-03 | 2020-01-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Rho GTPase conformational single domain antibodies and uses thereof |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| DK3270965T3 (da) * | 2015-03-18 | 2020-06-08 | Seattle Genetics Inc | Cd48-antistoffer og konjugater deraf |
| KR102476846B1 (ko) * | 2016-02-05 | 2022-12-12 | 주식회사 헬릭스미스 | 항―ｃ―ＭＥＴ 항체 및 이의 용도 |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| RU2735918C2 (ru) * | 2018-06-07 | 2020-11-10 | Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" | Набор реагентов для выявления маркера эпителиальных карцином |
| EP3816186A4 (en) * | 2018-06-29 | 2022-04-06 | Suzhou Smartnuclide Biopharmaceutical Co., Ltd. | PD-L1 BINDING POLYPEPTIDES AND USE THEREOF |
| KR102396194B1 (ko) * | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| US20220252603A1 (en) * | 2019-06-06 | 2022-08-11 | Apollomics Inc. (Hangzhou) | Method for treating cancer patients using c-met inhibitor |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| EP4129335A4 (en) | 2020-09-01 | 2024-04-24 | RemeGen Co., Ltd. | ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS |
| WO2022055893A1 (en) * | 2020-09-08 | 2022-03-17 | Ideaya Biosciences Inc. | Pharmaceutical combination and tumor treatment |
| JP2025524370A (ja) * | 2022-06-09 | 2025-07-30 | サンタ アナ バイオ インコーポレイテッド | ｃ－Ｋｉｔ及び／またはｓｉｇｌｅｃを標的とする抗体ならびにその使用 |
| IL318499A (en) | 2022-07-30 | 2025-03-01 | Pinetree Therapeutics Inc | Compounds for targeted lysosomal degradation and methods of using them |
| AU2024323801A1 (en) * | 2023-08-14 | 2026-03-19 | Minghui Pharmaceutical (Hangzhou) Limited | Anti-c-met nanobody and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| EP1516185A4 (en) * | 2001-12-27 | 2007-06-20 | Van Andel Res Inst | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| WO2007056523A2 (en) * | 2005-11-08 | 2007-05-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing and monitoring the progression of cancer |
| ES2368864T3 (es) * | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
-
2009
- 2009-08-21 EP EP09305777A patent/EP2287197A1/en not_active Withdrawn
-
2010
- 2010-08-23 EP EP10744608.0A patent/EP2467402B1/en active Active
- 2010-08-23 BR BR112012003759A patent/BR112012003759A2/pt not_active Application Discontinuation
- 2010-08-23 TW TW099128075A patent/TW201111781A/zh unknown
- 2010-08-23 NZ NZ700437A patent/NZ700437A/en unknown
- 2010-08-23 RU RU2012109004/10A patent/RU2582265C2/ru active
- 2010-08-23 AR ARP100103069A patent/AR077901A1/es not_active Application Discontinuation
- 2010-08-23 CA CA2769427A patent/CA2769427C/en active Active
- 2010-08-23 CN CN201080036635.7A patent/CN102639564B/zh active Active
- 2010-08-23 KR KR1020127005757A patent/KR20120051734A/ko not_active Withdrawn
- 2010-08-23 AU AU2010284944A patent/AU2010284944B2/en active Active
- 2010-08-23 MX MX2012002139A patent/MX2012002139A/es not_active Application Discontinuation
- 2010-08-23 JP JP2012525183A patent/JP5951486B2/ja active Active
- 2010-08-23 WO PCT/EP2010/062271 patent/WO2011020925A1/en not_active Ceased
- 2010-08-23 IN IN1322DEN2012 patent/IN2012DN01322A/en unknown
- 2010-08-23 SG SG2012009106A patent/SG178339A1/en unknown
- 2010-08-23 US US13/391,435 patent/US8673302B2/en active Active
- 2010-08-23 ES ES10744608.0T patent/ES2692522T3/es active Active
- 2010-08-23 NZ NZ598194A patent/NZ598194A/en unknown
-
2012
- 2012-02-19 IL IL218202A patent/IL218202A/en active IP Right Grant
- 2012-03-20 ZA ZA2012/02076A patent/ZA201202076B/en unknown
-
2014
- 2014-01-24 US US14/163,501 patent/US20140295452A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201111781A (en) | 2011-04-01 |
| NZ598194A (en) | 2015-05-29 |
| MX2012002139A (es) | 2012-03-07 |
| NZ700437A (en) | 2016-04-29 |
| SG178339A1 (en) | 2012-03-29 |
| ES2692522T3 (es) | 2018-12-04 |
| US20120149031A1 (en) | 2012-06-14 |
| ZA201202076B (en) | 2012-11-28 |
| JP5951486B2 (ja) | 2016-07-13 |
| JP2013502213A (ja) | 2013-01-24 |
| IL218202A (en) | 2017-07-31 |
| EP2467402B1 (en) | 2018-08-01 |
| CN102639564A (zh) | 2012-08-15 |
| EP2287197A1 (en) | 2011-02-23 |
| IL218202A0 (en) | 2012-04-30 |
| CA2769427A1 (en) | 2011-02-24 |
| EP2467402A1 (en) | 2012-06-27 |
| WO2011020925A1 (en) | 2011-02-24 |
| KR20120051734A (ko) | 2012-05-22 |
| RU2012109004A (ru) | 2013-09-27 |
| CA2769427C (en) | 2020-03-10 |
| AU2010284944A1 (en) | 2012-03-08 |
| US20140295452A1 (en) | 2014-10-02 |
| AU2010284944B2 (en) | 2016-01-28 |
| US8673302B2 (en) | 2014-03-18 |
| RU2582265C2 (ru) | 2016-04-20 |
| AR077901A1 (es) | 2011-09-28 |
| IN2012DN01322A (cg-RX-API-DMAC7.html) | 2015-06-05 |
| CN102639564B (zh) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012003759A2 (pt) | "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer." | |
| HUS2100038I1 (hu) | Anti-CD20 antitest készítmények | |
| PT2376535T (pt) | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t | |
| BRPI0923231A2 (pt) | anticorpo anti-cmet. | |
| BRPI1008692A2 (pt) | moléculas de anticorpos tendo especificidade para ox40 humano. | |
| BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
| BRPI1016234A2 (pt) | dispositivo aplicador para uso médico e/ou cosmético. | |
| BRPI1008740A2 (pt) | Proteínas pesticidas e métodos para seu uso. | |
| BRPI1010621A2 (pt) | derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso | |
| PL2411408T3 (pl) | Rozpuszczalne przeciwciała "tylko cieżkołańcuchowe" | |
| BRPI0816919A2 (pt) | Redução de infecções concomitantes em porcos pelo uso de antígeno pcv2. | |
| IL235261B (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| IL223604B (en) | System for detection of an analyte in a body fluid | |
| BRPI0806589A2 (pt) | Catalisador, sua preparação e uso. | |
| BRPI0911679A2 (pt) | composto aciltiouréia, ou sal do mesmo, e seu uso | |
| DE602006008736D1 (de) | Berührungsloses Bildaufnahmegerät | |
| BRPI0821276A2 (pt) | Produto, e, uso do produto | |
| BR112012005208A2 (pt) | antiocorpos contra o receptor de glucagon e seu uso | |
| BRPI0718192A2 (pt) | Corantes dispersos, sua preparação e seu uso. | |
| BRPI1012924A2 (pt) | derivados de amilóide p de soro e sua preparação e uso. | |
| BRPI0906444A2 (pt) | Compostos de 4-piridinona e seu uso para câncer | |
| BRPI0816778A2 (pt) | Sistema de infusão e transferência para uso com agentes radioativos | |
| BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |